Generation Bio (NASDAQ:GBIO) Upgraded at Zacks Research

Zacks Research upgraded shares of Generation Bio (NASDAQ:GBIO) to a hold rating in a report released on Monday,Zacks.com reports.

Several other brokerages also recently commented on GBIO. Wedbush set a $5.50 target price on Generation Bio and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $11.00 to $5.00 in a research report on Tuesday, December 16th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 target price on shares of Generation Bio in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Finally, Citigroup restated a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Generation Bio currently has a consensus rating of “Hold” and a consensus price target of $8.88.

Generation Bio Price Performance

GBIO opened at $5.58 on Monday. Generation Bio has a fifty-two week low of $3.00 and a fifty-two week high of $9.02. The company’s 50 day moving average price is $5.45 and its two-hundred day moving average price is $5.55. The firm has a market capitalization of $37.61 million, a price-to-earnings ratio of -0.60 and a beta of 2.05.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $0.66 million. As a group, equities research analysts predict that Generation Bio will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Shay Capital LLC bought a new position in Generation Bio during the third quarter worth $64,000. ADAR1 Capital Management LLC acquired a new position in shares of Generation Bio during the third quarter valued at about $136,000. AQR Capital Management LLC bought a new position in shares of Generation Bio during the 1st quarter worth about $36,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Generation Bio in the 3rd quarter valued at about $606,000. Finally, Marshall Wace LLP bought a new stake in Generation Bio in the 2nd quarter valued at about $37,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.